Tildrakizumab for the treatment of moderate to severe psoriasis: Results from a single center preliminary real‐life study
2022; Wiley; Volume: 35; Issue: 12 Linguagem: Inglês
10.1111/dth.15941
ISSN1529-8019
AutoresAngelo Ruggiero, Luca Potestio, Sara Cacciapuoti, Lucia Gallo, Teresa Battista, Elisa Camela, Gabriella Fabbrocini, Matteo Megna,
Tópico(s)Autoimmune Bullous Skin Diseases
ResumoDermatologic TherapyVolume 35, Issue 12 e15941 LETTER Tildrakizumab for the treatment of moderate to severe psoriasis: Results from a single center preliminary real-life study Angelo Ruggiero, Corresponding Author Angelo Ruggiero [email protected] orcid.org/0000-0002-4658-7391 Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy Correspondence Angelo Ruggiero, Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy. Email: [email protected]Search for more papers by this authorLuca Potestio, Luca Potestio orcid.org/0000-0001-5940-0592 Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalySearch for more papers by this authorSara Cacciapuoti, Sara Cacciapuoti Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalySearch for more papers by this authorLucia Gallo, Lucia Gallo Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalySearch for more papers by this authorTeresa Battista, Teresa Battista Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalySearch for more papers by this authorElisa Camela, Elisa Camela orcid.org/0000-0001-7201-9163 Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalySearch for more papers by this authorGabriella Fabbrocini, Gabriella Fabbrocini orcid.org/0000-0002-0064-1874 Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalySearch for more papers by this authorMatteo Megna, Matteo Megna orcid.org/0000-0003-1803-2046 Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalySearch for more papers by this author Angelo Ruggiero, Corresponding Author Angelo Ruggiero [email protected] orcid.org/0000-0002-4658-7391 Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy Correspondence Angelo Ruggiero, Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy. Email: [email protected]Search for more papers by this authorLuca Potestio, Luca Potestio orcid.org/0000-0001-5940-0592 Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalySearch for more papers by this authorSara Cacciapuoti, Sara Cacciapuoti Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalySearch for more papers by this authorLucia Gallo, Lucia Gallo Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalySearch for more papers by this authorTeresa Battista, Teresa Battista Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalySearch for more papers by this authorElisa Camela, Elisa Camela orcid.org/0000-0001-7201-9163 Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalySearch for more papers by this authorGabriella Fabbrocini, Gabriella Fabbrocini orcid.org/0000-0002-0064-1874 Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalySearch for more papers by this authorMatteo Megna, Matteo Megna orcid.org/0000-0003-1803-2046 Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalySearch for more papers by this author First published: 14 October 2022 https://doi.org/10.1111/dth.15941Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1Megna M, Cinelli E, Gallo L, Camela E, Ruggiero A, Fabbrocini G. Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period. Arch Dermatol Res. 2022 Aug; 314(6): 619-623. 10.1007/s00403-021-02200-7 CASPubMedWeb of Science®Google Scholar 2Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Megna M. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clin Exp Dermatol. 2021; 47: 561-567. doi:10.1111/ced.14979 10.1111/ced.14979 PubMedWeb of Science®Google Scholar 3Sinclair R, Thirthar PV. Tildrakizumab for the treatment of psoriasis. Expert Rev Clin Immunol. 2019; 15(1): 5-12. 10.1080/1744666X.2019.1544493 CASPubMedWeb of Science®Google Scholar 4Burlando M, Castelli R, Cozzani E, et al. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs Context. 2021; 10:2021-2-6. PubMedGoogle Scholar 5Drerup KA, Seemann C, Gerdes S, et al. Effective and safe treatment of psoriatic disease with the anti-IL-23p19 biologic tildrakizumab: results of a real-world prospective cohort study in nonselected patients. Dermatology. 2022; 238(4):615-619. 10.1159/000519924 PubMedWeb of Science®Google Scholar 6Narcisi A, Valenti M, Cortese A, et al. Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: a single-center retrospective comparative study. Dermatol Ther. 2022; 35(2):e15228. 10.1111/dth.15228 CASPubMedWeb of Science®Google Scholar 7Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022; 1-8. 10.1080/09546634.2022.2081655 Web of Science®Google Scholar 8Megna M, Ruggiero A, Camela E, Fabbrocini G, Marasca C. A case of erythrodermic psoriasis successfully treated with guselkumab. Dermatol Ther. 2020; 33(2):e13238. doi:10.1111/dth.13238 10.1111/dth.13238 PubMedWeb of Science®Google Scholar 9 European Medicines Agency. Assessment report. Ilumetri. International non-proprietary name: tildrakizumab. Procedure no. EMEA/H/C/004514/0000; 2018. https://www.ema.europa.eu. Google Scholar 10Megna M, Potestio L, Camela E, et al. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-center retrospective study in a real-life setting. Dermatol Ther. 2022;e15667. PubMedWeb of Science®Google Scholar 11Caldarola G, Galluzzo M, Bernardini N, et al. Tildrakizumab in moderate-to-severe plaque psoriasis: a multicenter, retrospective, real-life study. Dermatol Ther. 2022 Jun; 35(6):e15488. doi:10.1111/dth.15488 10.1111/dth.15488 CASPubMedWeb of Science®Google Scholar 12Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of tildrakizumab for the treatment of difficult-to-treat areas: scalp, nail, palmoplantar and genital psoriasis. J Clin Med. 2022; 11(9): 2631. doi:10.3390/jcm11092631 10.3390/jcm11092631 CASPubMedWeb of Science®Google Scholar Volume35, Issue12December 2022e15941 ReferencesRelatedInformation
Referência(s)